Differential selectivity in carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2001-11

AUTHORS

Yasuhiro Masubuchi, Tomohisa Nakano, Atsushi Ose, Toshiharu Horie

ABSTRACT

. Oxidative metabolism of carbamazepine results in covalent binding of its reactive metabolite to liver microsomal proteins, which has been proposed as an important event in pathogenesis of the hypersensitivity reactions to this drug. Although the proposed reactive metabolites are produced by cytochrome P450 enzymes (P450 or CYP), the impact of the formation of unstable metabolites on the enzyme itself has not been elucidated. The present study examines the alteration of P450 enzyme activities during the metabolism of carbamazepine. Liver microsomes from rats and humans were preincubated with carbamazepine in the presence of NADPH, and subsequently assayed for monooxygenase activities representing several P450s. No evidence was obtained for inactivation of CYP2C11, CYP3A, CYP1A1/2 or CYP2B1/2 in rat liver microsomes during the carbamazepine metabolism, whereas the CYP2D enzyme was inactivated in a manner related to the preincubation time. Interestingly, under the same protocol human liver microsomes did not exhibit inactivation of CYP2D6, as well as there being no CYP2C8, CYP2C9 or CYP3A4 inactivation, whereas CYP1A2 was inactivated. Reduced glutathione could not protect against the observed inactivation of the P450s. These results suggest that CYP2D enzyme(s) in rats and CYP1A2 in humans biotransform carbamazepine into reactive metabolites, resulting in inactivation of the enzyme themselves, and raise the possibility that the P450 isoforms participate in toxicity induced by the drug in both animal species. More... »

PAGES

538-543

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002040100270

DOI

http://dx.doi.org/10.1007/s002040100270

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1030947154

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11760814


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticonvulsants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carbamazepine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytochrome P-450 Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytochrome P-450 Enzyme System", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "In Vitro Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Microsomes, Liver", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats, Wistar", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Species Specificity", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1\u201333 Yayoi-cho, Inage-ku, Chiba 263\u20138522, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1\u201333 Yayoi-cho, Inage-ku, Chiba 263\u20138522, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masubuchi", 
        "givenName": "Yasuhiro", 
        "id": "sg:person.01062163410.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062163410.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1\u201333 Yayoi-cho, Inage-ku, Chiba 263\u20138522, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1\u201333 Yayoi-cho, Inage-ku, Chiba 263\u20138522, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakano", 
        "givenName": "Tomohisa", 
        "id": "sg:person.01133370071.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133370071.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1\u201333 Yayoi-cho, Inage-ku, Chiba 263\u20138522, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1\u201333 Yayoi-cho, Inage-ku, Chiba 263\u20138522, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ose", 
        "givenName": "Atsushi", 
        "id": "sg:person.01073605407.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073605407.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1\u201333 Yayoi-cho, Inage-ku, Chiba 263\u20138522, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1\u201333 Yayoi-cho, Inage-ku, Chiba 263\u20138522, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Horie", 
        "givenName": "Toshiharu", 
        "id": "sg:person.015025434461.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015025434461.42"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2001-11", 
    "datePublishedReg": "2001-11-01", 
    "description": "Abstract. Oxidative metabolism of carbamazepine results in covalent binding of its reactive metabolite to liver microsomal proteins, which has been proposed as an important event in pathogenesis of the hypersensitivity reactions to this drug. Although the proposed reactive metabolites are produced by cytochrome P450 enzymes (P450 or CYP), the impact of the formation of unstable metabolites on the enzyme itself has not been elucidated. The present study examines the alteration of P450 enzyme activities during the metabolism of carbamazepine. Liver microsomes from rats and humans were preincubated with carbamazepine in the presence of NADPH, and subsequently assayed for monooxygenase activities representing several P450s. No evidence was obtained for inactivation of CYP2C11, CYP3A, CYP1A1/2 or CYP2B1/2 in rat liver microsomes during the carbamazepine metabolism, whereas the CYP2D enzyme was inactivated in a manner related to the preincubation time. Interestingly, under the same protocol human liver microsomes did not exhibit inactivation of CYP2D6, as well as there being no CYP2C8, CYP2C9 or CYP3A4 inactivation, whereas CYP1A2 was inactivated. Reduced glutathione could not protect against the observed inactivation of the P450s. These results suggest that CYP2D enzyme(s) in rats and CYP1A2 in humans biotransform carbamazepine into reactive metabolites, resulting in inactivation of the enzyme themselves, and raise the possibility that the P450 isoforms participate in toxicity induced by the drug in both animal species.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s002040100270", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1019669", 
        "issn": [
          "0340-5761", 
          "1432-0738"
        ], 
        "name": "Archives of Toxicology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "75"
      }
    ], 
    "keywords": [
      "liver microsomes", 
      "reactive metabolites", 
      "metabolism of carbamazepine", 
      "human liver microsomes", 
      "inactivation of CYP2D6", 
      "cytochrome P450", 
      "P450 enzyme activity", 
      "hypersensitivity reactions", 
      "carbamazepine metabolism", 
      "rat liver microsomes", 
      "P450 isoforms", 
      "carbamazepine results", 
      "rats", 
      "oxidative metabolism", 
      "CYP3A4 inactivation", 
      "human liver", 
      "reduced glutathione", 
      "CYP2D enzyme", 
      "preincubation time", 
      "carbamazepine", 
      "presence of NADPH", 
      "microsomal protein", 
      "CYP1A2", 
      "monooxygenase activity", 
      "present study", 
      "microsomes", 
      "drugs", 
      "metabolism", 
      "P450", 
      "metabolites", 
      "differential selectivity", 
      "inactivation", 
      "animal species", 
      "humans", 
      "CYP2C11", 
      "enzyme activity", 
      "pathogenesis", 
      "CYP3A", 
      "CYP2C8", 
      "CYP2D6", 
      "CYP2C9", 
      "CYP2D", 
      "liver", 
      "important events", 
      "activity", 
      "alterations", 
      "toxicity", 
      "covalent binding", 
      "unstable metabolites", 
      "enzyme", 
      "glutathione", 
      "isoforms", 
      "evidence", 
      "observed inactivation", 
      "study", 
      "protein", 
      "events", 
      "results", 
      "binding", 
      "NADPH", 
      "manner", 
      "presence", 
      "time", 
      "impact", 
      "possibility", 
      "reaction", 
      "formation", 
      "selectivity", 
      "species", 
      "inactivation of CYP2C11", 
      "same protocol human liver microsomes", 
      "protocol human liver microsomes", 
      "carbamazepine-induced inactivation"
    ], 
    "name": "Differential selectivity in carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver", 
    "pagination": "538-543", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1030947154"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002040100270"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11760814"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002040100270", 
      "https://app.dimensions.ai/details/publication/pub.1030947154"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_315.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s002040100270"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002040100270'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002040100270'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002040100270'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002040100270'


 

This table displays all metadata directly associated to this object as RDF triples.

208 TRIPLES      21 PREDICATES      113 URIs      105 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002040100270 schema:about N098e514b7352443183346ef4746643f4
2 N14773d9cb9c943c68632b6089bb992cc
3 N160bceded349460b9262ed550682df60
4 N1dd6e100ab074b33b1e7031f4d4c9e79
5 N2ebcdc8c61bf4eaa91188a6a14e5f11b
6 N31f83aa437bf426aaf3270043c0196f0
7 N659eb994b6c9489caccf491a66b5b2b0
8 N6cb4d4f9f6494dcf8dfecde74f4b8de8
9 N9978aa8f2bd44dfeb4a675c938b2ec22
10 Nc656bba2cfab4d9e9cb0811678a0ec84
11 Ncb4ebfd7b7674bc08c814c029305f54b
12 Ne22478ac1be74613a6c12065059c35b4
13 Ne818d7a190f742bcb91590071078b16e
14 anzsrc-for:11
15 anzsrc-for:1115
16 schema:author Na228ebc549cb48a4aff47b32c7e2f967
17 schema:datePublished 2001-11
18 schema:datePublishedReg 2001-11-01
19 schema:description Abstract. Oxidative metabolism of carbamazepine results in covalent binding of its reactive metabolite to liver microsomal proteins, which has been proposed as an important event in pathogenesis of the hypersensitivity reactions to this drug. Although the proposed reactive metabolites are produced by cytochrome P450 enzymes (P450 or CYP), the impact of the formation of unstable metabolites on the enzyme itself has not been elucidated. The present study examines the alteration of P450 enzyme activities during the metabolism of carbamazepine. Liver microsomes from rats and humans were preincubated with carbamazepine in the presence of NADPH, and subsequently assayed for monooxygenase activities representing several P450s. No evidence was obtained for inactivation of CYP2C11, CYP3A, CYP1A1/2 or CYP2B1/2 in rat liver microsomes during the carbamazepine metabolism, whereas the CYP2D enzyme was inactivated in a manner related to the preincubation time. Interestingly, under the same protocol human liver microsomes did not exhibit inactivation of CYP2D6, as well as there being no CYP2C8, CYP2C9 or CYP3A4 inactivation, whereas CYP1A2 was inactivated. Reduced glutathione could not protect against the observed inactivation of the P450s. These results suggest that CYP2D enzyme(s) in rats and CYP1A2 in humans biotransform carbamazepine into reactive metabolites, resulting in inactivation of the enzyme themselves, and raise the possibility that the P450 isoforms participate in toxicity induced by the drug in both animal species.
20 schema:genre article
21 schema:inLanguage en
22 schema:isAccessibleForFree false
23 schema:isPartOf N666e9737e5cf42d9a047e35760e8e918
24 Ne2f0b4f0a49b4777ac83c4fe1054d244
25 sg:journal.1019669
26 schema:keywords CYP1A2
27 CYP2C11
28 CYP2C8
29 CYP2C9
30 CYP2D
31 CYP2D enzyme
32 CYP2D6
33 CYP3A
34 CYP3A4 inactivation
35 NADPH
36 P450
37 P450 enzyme activity
38 P450 isoforms
39 activity
40 alterations
41 animal species
42 binding
43 carbamazepine
44 carbamazepine metabolism
45 carbamazepine results
46 carbamazepine-induced inactivation
47 covalent binding
48 cytochrome P450
49 differential selectivity
50 drugs
51 enzyme
52 enzyme activity
53 events
54 evidence
55 formation
56 glutathione
57 human liver
58 human liver microsomes
59 humans
60 hypersensitivity reactions
61 impact
62 important events
63 inactivation
64 inactivation of CYP2C11
65 inactivation of CYP2D6
66 isoforms
67 liver
68 liver microsomes
69 manner
70 metabolism
71 metabolism of carbamazepine
72 metabolites
73 microsomal protein
74 microsomes
75 monooxygenase activity
76 observed inactivation
77 oxidative metabolism
78 pathogenesis
79 possibility
80 preincubation time
81 presence
82 presence of NADPH
83 present study
84 protein
85 protocol human liver microsomes
86 rat liver microsomes
87 rats
88 reaction
89 reactive metabolites
90 reduced glutathione
91 results
92 same protocol human liver microsomes
93 selectivity
94 species
95 study
96 time
97 toxicity
98 unstable metabolites
99 schema:name Differential selectivity in carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver
100 schema:pagination 538-543
101 schema:productId N09ff6b2492454d34ba5b711672583f47
102 N2f2219039d754df693b5e13058f334ad
103 N9f63d2bbdcfb4fab8417917fe0a1f0b9
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030947154
105 https://doi.org/10.1007/s002040100270
106 schema:sdDatePublished 2022-01-01T18:10
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher Nb380c95d7dbc4a6784f27aa45585ef87
109 schema:url https://doi.org/10.1007/s002040100270
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N098e514b7352443183346ef4746643f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Anticonvulsants
115 rdf:type schema:DefinedTerm
116 N09ff6b2492454d34ba5b711672583f47 schema:name doi
117 schema:value 10.1007/s002040100270
118 rdf:type schema:PropertyValue
119 N14773d9cb9c943c68632b6089bb992cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Rats
121 rdf:type schema:DefinedTerm
122 N160bceded349460b9262ed550682df60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Cytochrome P-450 Enzyme System
124 rdf:type schema:DefinedTerm
125 N1dd6e100ab074b33b1e7031f4d4c9e79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name In Vitro Techniques
127 rdf:type schema:DefinedTerm
128 N220f7d86911444f2a66eb71fe345b2cd rdf:first sg:person.01133370071.28
129 rdf:rest Nfc23244bef614aad983419a70e79bf76
130 N2ebcdc8c61bf4eaa91188a6a14e5f11b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Animals
132 rdf:type schema:DefinedTerm
133 N2f2219039d754df693b5e13058f334ad schema:name pubmed_id
134 schema:value 11760814
135 rdf:type schema:PropertyValue
136 N31f83aa437bf426aaf3270043c0196f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Microsomes, Liver
138 rdf:type schema:DefinedTerm
139 N659eb994b6c9489caccf491a66b5b2b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Carbamazepine
141 rdf:type schema:DefinedTerm
142 N666e9737e5cf42d9a047e35760e8e918 schema:issueNumber 9
143 rdf:type schema:PublicationIssue
144 N6cb4d4f9f6494dcf8dfecde74f4b8de8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 N9978aa8f2bd44dfeb4a675c938b2ec22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Male
149 rdf:type schema:DefinedTerm
150 N9f63d2bbdcfb4fab8417917fe0a1f0b9 schema:name dimensions_id
151 schema:value pub.1030947154
152 rdf:type schema:PropertyValue
153 Na228ebc549cb48a4aff47b32c7e2f967 rdf:first sg:person.01062163410.74
154 rdf:rest N220f7d86911444f2a66eb71fe345b2cd
155 Nb380c95d7dbc4a6784f27aa45585ef87 schema:name Springer Nature - SN SciGraph project
156 rdf:type schema:Organization
157 Nc656bba2cfab4d9e9cb0811678a0ec84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Enzyme Inhibitors
159 rdf:type schema:DefinedTerm
160 Ncb4ebfd7b7674bc08c814c029305f54b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Rats, Wistar
162 rdf:type schema:DefinedTerm
163 Ne22478ac1be74613a6c12065059c35b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Species Specificity
165 rdf:type schema:DefinedTerm
166 Ne2f0b4f0a49b4777ac83c4fe1054d244 schema:volumeNumber 75
167 rdf:type schema:PublicationVolume
168 Ne537304adafa4581a63fb723b8e13e78 rdf:first sg:person.015025434461.42
169 rdf:rest rdf:nil
170 Ne818d7a190f742bcb91590071078b16e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Cytochrome P-450 Enzyme Inhibitors
172 rdf:type schema:DefinedTerm
173 Nfc23244bef614aad983419a70e79bf76 rdf:first sg:person.01073605407.52
174 rdf:rest Ne537304adafa4581a63fb723b8e13e78
175 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
176 schema:name Medical and Health Sciences
177 rdf:type schema:DefinedTerm
178 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
179 schema:name Pharmacology and Pharmaceutical Sciences
180 rdf:type schema:DefinedTerm
181 sg:journal.1019669 schema:issn 0340-5761
182 1432-0738
183 schema:name Archives of Toxicology
184 schema:publisher Springer Nature
185 rdf:type schema:Periodical
186 sg:person.01062163410.74 schema:affiliation grid-institutes:grid.136304.3
187 schema:familyName Masubuchi
188 schema:givenName Yasuhiro
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062163410.74
190 rdf:type schema:Person
191 sg:person.01073605407.52 schema:affiliation grid-institutes:grid.136304.3
192 schema:familyName Ose
193 schema:givenName Atsushi
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073605407.52
195 rdf:type schema:Person
196 sg:person.01133370071.28 schema:affiliation grid-institutes:grid.136304.3
197 schema:familyName Nakano
198 schema:givenName Tomohisa
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133370071.28
200 rdf:type schema:Person
201 sg:person.015025434461.42 schema:affiliation grid-institutes:grid.136304.3
202 schema:familyName Horie
203 schema:givenName Toshiharu
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015025434461.42
205 rdf:type schema:Person
206 grid-institutes:grid.136304.3 schema:alternateName Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1–33 Yayoi-cho, Inage-ku, Chiba 263–8522, Japan
207 schema:name Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1–33 Yayoi-cho, Inage-ku, Chiba 263–8522, Japan
208 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...